ECSP034475A - Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 - Google Patents

Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1

Info

Publication number
ECSP034475A
ECSP034475A EC2003004475A ECSP034475A ECSP034475A EC SP034475 A ECSP034475 A EC SP034475A EC 2003004475 A EC2003004475 A EC 2003004475A EC SP034475 A ECSP034475 A EC SP034475A EC SP034475 A ECSP034475 A EC SP034475A
Authority
EC
Ecuador
Prior art keywords
lower alkyl
halogen
cyano
hydroxy
hydrogen
Prior art date
Application number
EC2003004475A
Other languages
English (en)
Inventor
Thierry Godel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP034475A publication Critical patent/ECSP034475A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se regiere a compuestos con fórmula general (gráfico) donde r es hidrógeno 0 halógeno R1 es-(C=C) mR1 o -CR´ =CR") mR1 donde R1 es a) halógeno, t B) ciano, o los siguientes grupos: (Gráfico) d) -C(NR'r", e) -C(0)0(CH2)mR5, f) -C(0)R5, g) -N(OH)-(CH2)mR5, h) -NR'C(0)-(CH2)mR5, i) -N [C(0)-R']2, j -OR6, -(CH2)m-SR6,-(CH2)m-S(0)R6, o-(CH2)m-S(0)2R6. 1) Arilo,opcionalmente sustituido para uno o más sustituyentes, seleccionados a partir de halógeno, trifluorometilo, alquilo inferior, alcoxi inferior, ciano, hidroxi, -NR'R", nitro,-(CH2)nOR', -C(O)NR'R", -C(0)OR'or-C(O)R', m) es un grupo heteroarilo de cinco o seis miembros, conteniendo de uno a cuatro heteroátomos, seleccionandos a partir de N,0 6 ó S y puede ser opcionalmente sustituido por uno o más sustituyentes, seleccionados a partir de halógeno, trifluorometilo, alquilo inferior, alcoxi inferior, ciano, hidroxi, -NR'R", nitro, -(CH2)nOR', -C(0)OR', - C(0)NR'R" 0 -C(=)R', n) es una amina terciaria cíclica saturada de cinco o seis miembros, del grupo la cual puede contener un heteroátomo adicional, sleccionado entre N, 00 S. R'R" son, independientemente uno de otro, hidrógeno, hidroxi, alquilo inferior, cicloalquilo ó arilo, donde el alquilo inferior, grupos cicloalquilo ó arilo pueden ser opcionalmente sustituídos por uno o más sustituyentes, ' seleccionados a partir de halógeno, trifluorometilo, alquilo inferior, alcoxi inferior, ciano, hidroxi, -NR"'R"", nitro, (CH2)nOR"', -c(0)NR"'r"", -C(0)OR"' O -C(0)R"". R"'/R"" son, independientemente uno de otro, hidrógeno, alquilo inferior, cicloalquilo o arilo, R5 es hidrógeno, ciano, hidroxi, halógeno, trifluorometilo, -C(0)OR', OC(0)R', -OC(0)R 0 arilo, opcionalmente sustituidos por uno o más sustituyentes seleccionados a partir de halógeno, trifluorometilo, alquilo inferior, alcoxi inferior, ciano, hidroxi, -NR'R", nitro, -(CHZ)nOR', -C(0)NR'R", -C(0) OR' o-C(0)OR', o es un grupo heteroarilo de cinco o seis miembros,conteniendo de uno a cuatro heteroatomos, seleccionados a partir de N, 0 o S y puede ser opcionalmente sustituido por uno o más sustituyentes, seleccionados a partir de halógeno, trifluorometilo, alquilo inferior, alcoxi inferior, ciano, hidroxi, -NR'R", nitro, -(CH2) n OR', -C(0)NR'R", -C(0) OR' or -C to) R', R6 es hidrógeno, alquilo inferior, trifluorometilo, o arilo, donde el alquilo inferior o el grupo arilo pueden ser opcionalmente sustituidos por uno o más sustituyentes seleccionados a partir de halógeno, trifluorometilo, alquilo inferior , alcoxi inferior, ciano, hidroxi, -NR'R", nitro, -(CH2)nOR', -(CH2)nOR', -C(0)OR', -C(0)OR' o -C(0)R', o es un grupo heteroarilo de cinco o seis miembros, conteniendo de uno a cuatro heteroatomos, seleccionados a partir de N, 0 o S y puede ser opcionalmente sustituidos por uno o más sustituyentes, seleccionados a partir de halógeno, trifluorometilo, alquilo inferior, ciano, hidroxi, -NR'R", nitro -(CHz)nOR', -c(0) NR'R"' -c(0)OR'0 -C(0)R', R7 ES -C(0) -(CHZ)m OH o un grupo oxo; R2 hidrógeno, alquilo inferior, alcoxi inferior, halógeno o CF3; R3/R3, son independientemente uno de otro hidrógeno , alquilo inferior o forman juntos, con el átomo de carbón con el que se unen, un grupo cicloalquilo; R4/R4, son independientemente uno de otro hidrógeno, halógeno, CF3, alquilo inferior o alcoxi inferior; r y R2 o R4 y R4, pueden ser juntos -CH=CH=CH=CH-, opcionalmente sustituidos por uno o dos sustituyentes seleccionados a partir de alquilo inferior, halógeno o alcoxi inferior; X es -C(0) N(R8)-, (CH2)p0-, (CH2)pN(R8)-, -N(R8)C(0)-o -N(R8)- (CH2)p; donde R8 es hidrógeno o alquilo inferior ; n es 1 o 2; m es 0,1,2,3 o 4; o es 1 o 2; y p es 1 o 2; y sales de adición de ácido farmacéuticamente aceptables. Se ha encontrado que los compuestos de la presente invención son antagonistas del receptor de la Neuroquinina 1 (NK-1, sustancia P), y por lo tanto son útiles para el tratamiento de enfermedades relacionadas con este receptor.
EC2003004475A 2000-08-08 2003-02-07 Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 ECSP034475A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00117003 2000-08-08

Publications (1)

Publication Number Publication Date
ECSP034475A true ECSP034475A (es) 2003-03-31

Family

ID=8169466

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004475A ECSP034475A (es) 2000-08-08 2003-02-07 Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1

Country Status (36)

Country Link
US (1) US6770637B2 (es)
EP (1) EP1309559B1 (es)
JP (1) JP4053877B2 (es)
KR (1) KR100518201B1 (es)
CN (1) CN1293056C (es)
AR (1) AR030324A1 (es)
AT (1) ATE328871T1 (es)
AU (2) AU2002212118B2 (es)
BR (1) BR0113173A (es)
CA (1) CA2418868C (es)
CZ (1) CZ2003684A3 (es)
DE (1) DE60120419T2 (es)
DK (1) DK1309559T3 (es)
EC (1) ECSP034475A (es)
ES (1) ES2264706T3 (es)
GT (1) GT200100160A (es)
HR (1) HRP20030055A2 (es)
HU (1) HUP0301671A3 (es)
IL (2) IL154079A0 (es)
JO (1) JO2371B1 (es)
MA (1) MA27680A1 (es)
MX (1) MXPA03001143A (es)
MY (1) MY128993A (es)
NO (1) NO324841B1 (es)
NZ (1) NZ523751A (es)
PA (1) PA8524401A1 (es)
PE (1) PE20020332A1 (es)
PL (1) PL359849A1 (es)
PT (1) PT1309559E (es)
RU (1) RU2277087C2 (es)
SI (1) SI1309559T1 (es)
TW (1) TWI259180B (es)
UY (1) UY26872A1 (es)
WO (1) WO2002016324A1 (es)
YU (1) YU8703A (es)
ZA (1) ZA200300614B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
EP1688408A3 (en) * 2002-08-08 2007-08-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
AR041191A1 (es) 2002-08-08 2005-05-04 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos
JP2007521276A (ja) * 2003-06-25 2007-08-02 スミスクライン・ビーチャム・コーポレイション Ｎｋ−２およびｎｋ−３として用いるための４−カルボキサミドキノリン誘導体
DE602004008631T2 (de) * 2003-07-03 2008-07-10 F. Hoffmann-La Roche Ag Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
CA2572645C (en) * 2004-07-06 2011-01-18 F. Hoffmann-La Roche Ag Process for preparing carboxamide derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
BRPI0418939A (pt) * 2004-07-06 2008-04-08 Xenon Pharmaceuticals Inc derivados de nicotinamida e sua utilização como agentes terapêuticos
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 호프만-라 로슈 아게 Ｎｋ-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
WO2006089311A1 (en) 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2006089674A2 (en) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
MX2007012213A (es) * 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
WO2006113261A2 (en) * 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
EP1912983B1 (en) * 2005-08-11 2011-06-08 Vertex Pharmaceuticals, Inc. Modulators of cystic fibrosis transmembrane conductance regulator
MY145713A (en) 2005-09-09 2012-03-30 Smithkline Beecham Corp Hexahydropyrazino [2,1-c][1,4]oxazin-8(1h)-yl pyridine derivatives and their use in the treatment of psychotic disorders
KR101331768B1 (ko) 2005-11-08 2013-11-22 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
PL2674428T3 (pl) 2006-04-07 2017-01-31 Vertex Pharmaceuticals Incorporated Modulatory transporterów z kasetą wiążącą ATP
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CA2686838C (en) 2007-05-09 2017-03-14 Vertex Pharmaceuticals Incorporated Modulators of cftr
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
DK2639223T3 (en) 2007-12-07 2017-06-19 Vertex Pharma Process for Preparation of Cycloalkylcarboxiamido-pyridine Benzoic Acids
HRP20170241T2 (hr) 2007-12-07 2023-03-17 Vertex Pharmaceuticals Incorporated Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
NZ736561A (en) 2008-02-28 2018-02-23 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
UA107088C2 (xx) * 2009-09-11 2014-11-25 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
WO2011054773A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Novel lactam compounds
FR2954315B1 (fr) * 2009-12-23 2012-02-24 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RS54783B1 (sr) 2010-04-07 2016-10-31 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
DK3150198T3 (da) 2010-04-07 2021-11-01 Vertex Pharma Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
EP2760833A1 (en) * 2011-09-30 2014-08-06 Endo Pharmaceuticals Inc. Pyridine derivatives
US8809372B2 (en) * 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
MX357328B (es) 2011-11-08 2018-07-05 Vertex Pharma Moduladores de trasportadores de casete enlazante de atp.
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
ES2671418T3 (es) 2013-11-08 2018-06-06 Kissei Pharmaceutical Co., Ltd. Derivado de carboximetilpiperidina
RU2718044C2 (ru) 2013-11-12 2020-03-30 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
RS62140B1 (sr) 2014-04-15 2021-08-31 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
HRP20211194T1 (hr) 2014-11-18 2021-10-29 Vertex Pharmaceuticals Inc. Postupak za provođenje testova velike propusnosti putem tekućinske kromatografije visoke djelotvornosti
WO2016149324A1 (en) * 2015-03-16 2016-09-22 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
AU2016377658B2 (en) 2015-12-22 2022-09-29 Endosome Therapeutics, Inc. Tripartite modulators of endosomal G protein-coupled receptors
MX2022005867A (es) 2019-11-15 2022-06-14 Kandy Therapeutics Ltd Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2 -metilfenil)piridin-3-amina, un intermediario clave de nt-814.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56106286A (en) 1980-01-28 1981-08-24 Nippon Musical Instruments Mfg Electronic musical instrument
EP0103545A3 (en) 1982-09-13 1984-10-03 Arc Technologies Systems, Ltd. Electrode for arc furnaces
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
EP0532515B1 (en) * 1990-05-31 1996-10-23 Pfizer Inc. Preparation of substituted piperidines
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
NZ277839A (en) 1993-12-29 1998-01-26 Merck Sharp & Dohme Substituted morpholine derivatives, preparation and pharmaceutical compositions thereof
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
NO309272B1 (no) * 1995-03-24 2001-01-08 Takeda Chemical Industries Ltd Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
WO1998021185A1 (en) * 1996-11-08 1998-05-22 Sankyo Company, Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
EP1140067A1 (en) * 1999-01-07 2001-10-10 Warner-Lambert Company Antiviral method using mek inhibitors
DK1394150T3 (da) * 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
RU2238264C2 (ru) * 1999-02-24 2004-10-20 Ф.Хоффманн-Ля Рош Аг Производные бензола или пиридина и фармацевтическая композиция на их основе
WO2001028205A2 (en) * 1999-10-14 2001-04-19 Telefonaktiebolaget Lm Ericsson (Publ) System and method of retrieving voice mail messages in a telecommunications network
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide

Also Published As

Publication number Publication date
CA2418868C (en) 2010-02-02
NO20030632L (no) 2003-02-07
TWI259180B (en) 2006-08-01
US20020040040A1 (en) 2002-04-04
ZA200300614B (en) 2004-04-22
AU1211802A (en) 2002-03-04
KR20030022370A (ko) 2003-03-15
CN1610670A (zh) 2005-04-27
MA27680A1 (fr) 2006-01-02
DK1309559T3 (da) 2006-10-02
HRP20030055A2 (en) 2005-02-28
WO2002016324A1 (en) 2002-02-28
IL154079A0 (en) 2003-07-31
DE60120419T2 (de) 2007-06-06
IL154079A (en) 2008-03-20
CA2418868A1 (en) 2002-02-28
AR030324A1 (es) 2003-08-20
ATE328871T1 (de) 2006-06-15
NO20030632D0 (no) 2003-02-07
JP2004506718A (ja) 2004-03-04
NO324841B1 (no) 2007-12-17
CZ2003684A3 (cs) 2003-11-12
JO2371B1 (en) 2006-12-12
AU2002212118B2 (en) 2005-12-15
SI1309559T1 (sl) 2006-10-31
GT200100160A (es) 2002-05-16
DE60120419D1 (de) 2006-07-20
EP1309559B1 (en) 2006-06-07
HUP0301671A3 (en) 2010-03-29
PT1309559E (pt) 2006-10-31
MY128993A (en) 2007-03-30
PL359849A1 (en) 2004-09-06
UY26872A1 (es) 2002-01-31
HK1076459A1 (en) 2006-01-20
PA8524401A1 (es) 2002-04-25
US6770637B2 (en) 2004-08-03
EP1309559A1 (en) 2003-05-14
HUP0301671A2 (hu) 2003-08-28
NZ523751A (en) 2004-08-27
ES2264706T3 (es) 2007-01-16
YU8703A (sh) 2006-05-25
JP4053877B2 (ja) 2008-02-27
MXPA03001143A (es) 2003-06-24
KR100518201B1 (ko) 2005-10-04
BR0113173A (pt) 2003-06-24
RU2277087C2 (ru) 2006-05-27
CN1293056C (zh) 2007-01-03
PE20020332A1 (es) 2002-05-10

Similar Documents

Publication Publication Date Title
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
ES2525763T3 (es) Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
CO2019011604A2 (es) Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR062680A1 (es) Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas
PT1289955E (pt) Piperidinas para utilizacao como antagonistas dos receptores da orexina
AR043436A1 (es) Tetrahidroisoquinolinas sustituidas para uso como moduladores 5-ht6
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR046938A1 (es) Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
UY27322A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
ECSP034431A (es) N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina
AR065863A1 (es) Derivados de imidazolidinona
PE20240886A1 (es) Compuestos espirociclicos
AR035815A1 (es) Derivados de piperidina, un proceso para su preparacion, composiciones y combinaciones farmacéuticas que comprenden a dichos derivados
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
AR051753A1 (es) Metodos para preparar compuestos de indazol
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
AR039651A1 (es) Derivados de isoquinolina
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
PE75199A1 (es) Derivado de quinolina util como antagonista de neuroquinina